Abstract

Background

Decision making processes regarding new vaccine prioritizations are complex. The objective of this study was to prioritize the introduction of new vaccines in Indonesia.

Methods

A multi-criteria decision analysis (MCDA) was applied in this study. A preliminary data collection form was developed to collect country-specific data in relation to 30 pre-defined attributes. In particular, an open-ended questionnaire was conducted among targeted respondents from global level, national level and vaccine manufacturers, which were involved in the financial flows of new vaccine procurement in Indonesia. For setting new vaccines priorities, targeted respondents were asked to assign weight on 10 selected criteria.

Results

Top 3 attributes with the highest weight from respondents were premature deaths averted per year, incidents cases prevented per year, and cost-effectiveness. Applying criteria scores and weight assessment, the result showed that PCV, rotavirus, HPV, and JE would be on the 1^st, 2^nd, 3^rd and 4^th rank for setting new vaccine priority in Indonesia. There was a significant difference score (p value <0.05) between all these vaccines.

Conclusions

PCV, rotavirus and HPV vaccines should be more prioritized than JE vaccine. This ranking is in line with the WHO’s priority list, potentially illustrating the validity and usefulness of our MCDA-approach.

中文翻译：

---

通过使用策略性多属性疫苗分级工具（SMART疫苗）的框架进行多标准决策分析，优先考虑在印度尼西亚引入新疫苗

摘要

背景

关于新疫苗优先次序的决策过程很复杂。这项研究的目的是优先考虑在印度尼西亚引入新疫苗。

方法

一项多标准决策分析（MCDA）被应用在这项研究中。开发了初步的数据收集表格，以收集与30个预定义属性相关的特定于国家/地区的数据。特别是，对来自全球，国家和疫苗制造商的有针对性的受访者进行了不限成员名额调查问卷，这些受访者参与了印度尼西亚新疫苗采购的资金流动。为了确定新疫苗的优先级，要求目标受访者根据10个选定的标准分配权重。

结果

在受访者中权重最高的3大属性是：每年避免的过早死亡，每年避免的事件和成本效益。施加标准分数和重量评估，结果表明，PCV，轮状病毒，HPV，和JE将是对1^日，2^次，3^次和4^次秩为印度尼西亚设定新疫苗的优先级。所有这些疫苗之间都存在显着差异评分（p值<0.05）。

结论

PCV，轮状病毒和HPV疫苗应比JE疫苗优先。该排名与WHO的优先级列表一致，有可能说明我们的MCDA方法的有效性和实用性。